Latest Conference Articles

A lot is yet to be determined about the potential benefits of precision medicine in cardiology. As that field develops, there will also be questions about the varying benefits for men and women.

With extensive literature review and expert input, the ACR and the American Association of Hip and Knee Surgeons (AAHKS) have come together to propose a set of guidelines for medication during the perioperative period for patients undergoing knee or hip arthroplasty.

A PCSK9 inhibitor that reduces cholesterol by RNA interference instead of the monoclonal antibody approach appears effective and holds the promise of fewer injections and lower cost, researchers said today.

Praluent has been studied at a variety of levels and, now that it's been approved, there has been more insight on its benefits and risks.

With statins being a common treatment option to help patients reduce their cholesterol levels, the still relatively newly approved PCSK9 inhibitors have proven a valuable tool. However, they are not enough to help eliminate concerns about cardiac care and cholesterol.

Doctors prescribing Praluent for their patients have two dosing options to choose from. Studies on the treatment option have shown that the safety profile for both are good for patients.

In just over a year, Praluent has shown benefits in helping patients lower their cholesterol level. Despite the progress, there have also been some challenges.

Researchers who evaluated adverse events in a large sample of patients taking NSAIDs for arthritis came to a surprising conclusion: celecoxib is the safest of three drugs studied.

Left ventricular assist devices are usually associated with keeping patients alive while they wait for a heart transplant. Using the devices with aggressive drug therapy enabled some patients to recover heart function and forgo the pumps.

One of the biggest challenges cardiologists face is treating patients with atrial fibrillation who are undergoing percutaneous coronary intervention, particularly when it comes to prescribing anticoagulants.

Used for treatment of inflammation in rheumatic diseases, glucocorticoids are known to cause osteoporosis. The American College of Rheumatology has put forth new recommendations to hopefully decrease the frequency of bone fractures.

Prescribing rheumatologists discussed drug interactions, costs, contraindications, and severity of side effects with less than 50% of the patients in the study to whom they had prescribed disease-modifying antirheumatic drugs.

An analysis of thousands of patients in Germany taken from a national registry found interventional procedures more dangerous than surgery for severe symptomatic aortic valve stenosis. But there may have been confounding factors.

With ever-growing data that the inflammation in rheumatic conditions can go hand-in-hand with cardiovascular inflammation, two different studies seek to broaden rheumatology’s approach to dangerous conditions it may influence.

Nancy Lane, MD, shared a rheumatologist's perspective in treating patients who suffer pain and osteoporosis.

For doctors concerned about cardiovascular disease in patients, there have been some lingering questions about the best medications to prescribe.

A study comparing whether certain heart patients did better with bilateral arterial grafts than single grafts had the surprising result of finding no benefit at five years.

Nancy Lane, MD, discussed her team's study on abaloparatide, a new preparation of a hormone, and how it can stimulate bone formation.

Speaking at ACR 2016, the current chair of the Spondyloarthritis Research and Treatment Network (SPARTAN) presented data that showed that a combination of inflammatory drugs may inhibit ankylosis, the painful fusion of bones.

According to Lori Fitzpatrick, MD, additional findings showed that regardless of age, whether or not patients have had vertebral or non-vertebral fractures, treatment with abaloparatide worked.

Abaloparatide-sc can benefit postmenopausal women with osteoporosis by helping increase greater bone mineral density, since building bone strength is important for these women's health.

Systemic atherosclerosis causes peripheral artery disease, and these patients are at risk of cardiovascular death and stroke.

AHA President Steven Houser opens the AHA Scientific Sessions 2016 with a moving talk on his father's premature death from heart disease.

A new study out of Ireland examined the prevalence of extra-articular manifestations in axial spondyloarthritis, and found that women were at significantly higher risk for inflammatory bowel disease and uveitis than men.

A report out of Cedars-Sinai Medical Center shows a reduction in hip disease progression in ankylosing spondylitis patients who receive anti-tumor necrotics factor treatment.

Patients taken statins who survived heart attacks lived longer than those who did not take the drugs, a Taiwan research team found.

Certain types of inflammation go hand-in-hand. Columbia University researchers hypothesized that treatment that lowered arthritis disease activity would also decrease the risk of heart failure.

Philip Mease shared that he and his team are in the midst of preparing the content of the studies for publication to ensure continued education of psoriatic arthritis treatment.

At the ACR/ARHP annual meeting in Washington, DC, Philip Mease, MD, Swedish Medical Center, University of Washington, discussed the highlights from two psoriatic arthritis studies, OPAL Broaden and OPAL Beyond.

Using marijuana may double the risk of stress cardiomyopathy, researchers found.